CHANGES IN THE PREVALENCE AND MANAGEMENT OF CKD IN MEXICO CITY BETWEEN 1998-2004 AND 2015-2019

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/3cf36ed12ed7bae8a347bac619a3452d.pdf
CHANGES IN THE PREVALENCE AND MANAGEMENT OF CKD IN MEXICO CITY BETWEEN 1998-2004 AND 2015-2019

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Diego
Aguilar-Ramirez
Fernando Loyola-Nieto 0229774@up.edu.mx Universidad Panamericana Departamento de Epidemiología y Salud Pública, Escuela de Medicina Mexico City Mexico -
Eloisa Colin-Ramirez elcolin@up.edu.mx Universidad Panamericana Departamento de Epidemiología y Salud Pública, Escuela de Medicina Mexico City Mexico -
Alberto Nordmann-Gomes albertonordmann@hotmail.com Universidad Panamericana Departamento de Epidemiología y Salud Pública, Escuela de Medicina Mexico City Mexico -
Ana Paula Orgambide-Aguilar 0232656@up.edu.mx Columbia University Irving Medical Center Department of Medicine, Division of Rheumatology New York, New York United States -
Doreen Zhu doreen.zhu@ndph.ox.ac.uk University of Oxford Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health Oxford United Kingdom -
William G. Herrington will.herrington@ndph.ox.ac.uk University of Oxford Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health Oxford United Kingdom -
Jesus Alegre-Diaz inypcjad@gmail.com National Autonomous University of Mexico Experimental Research Unit from the Faculty of Medicine Mexico City Mexico -
Pablo Kuri-Morales kuripablo@tec.mx Instituto Tecnológico y de Estudios Superiores de Monterrey Proyecto oriGen Mexico City Mexico -
Roberto Tapia-Conyer tapiaconyer@gmail.com National Autonomous University of Mexico Faculty of Medicine Mexico City Mexico -
Diego Aguilar-Ramirez diego.aguilar-ramirez@ndph.ox.ac.uk University of Oxford Clinical Trial Service Unit & Epidemiological Studies Unit, Nuffield Department of Population Health Oxford United Kingdom *
Antonio Villa-Romero avilla@up.edu.mx Universidad Panamericana Departamento de Epidemiología y Salud Pública, Escuela de Medicina Mexico City Mexico -
Gregorio T Obrador gobrador@up.edu.mx Universidad Panamericana Departamento de Epidemiología y Salud Pública, Escuela de Medicina Mexico City Mexico -
-
-
-